In 2024, the pharmaceutical company Gilead announced that a single injection of lenacapavir protected 96 to 100 percent of recipients from HIV for up to six months. This article explains how they made it, how much it costs, and how we can help ensure it reaches those who need it most.
Read every article from Asimov Press at press.asimov.com.
